Clarify Health Solutions

The analytics layer healthcare forgot to build

Walk into the Clarify Health office in San Francisco and you will not find a wellness app, a wearable, or a chatbot that diagnoses your rash. You will find data engineers. A lot of them. They are building the thing nobody asked for at a venture capital pitch competition: the unsexy infrastructure that makes American healthcare's biggest, slowest experiment - value-based care - actually possible.

Today Clarify is a unicorn. Last valuation: $1.4 billion. Total raised: north of $400 million. Roughly 200 people. Sixty-plus health systems on the customer list. A platform called Atlas that has, by the company's own count, mapped more than 300 million patient journeys and produced over 18 billion AI-powered predictions. The numbers are big. The product is invisible to patients. That is the entire point.

A $4.5 trillion industry that cannot find its own data

The United States spends more on healthcare than any country on Earth and has the medical outcomes to make a Scandinavian shrug. Everyone who works in the system knows this. The puzzle has never been the diagnosis. The puzzle is the data.

Patient records sit inside electronic health systems that were designed for billing, not insight. Claims data lives at payers. Pharmacy data lives somewhere else again. Social determinants - housing, food, transportation - live nowhere at all, or live in a PDF a case manager wrote in 2019. To follow one human being from a primary care visit through a hip replacement and into rehab is, in most U.S. health systems, technically possible and operationally heroic.

This is the wall that value-based care keeps running into. You cannot pay providers for outcomes if you cannot measure outcomes. You cannot bundle a payment for an episode of care if you cannot define the episode. You cannot reward a network for keeping patients healthy if you cannot find the patients across the network.

A physician, two engineers, and the long way around

Jean Drouin is the kind of founder you do not bump into often. He is a medical doctor trained at Stanford. He spent years at McKinsey advising health systems on strategy and later helped build the firm's UK healthcare practice. He has briefed ministers. He has run consulting engagements that touched millions of lives without ever touching the patient.

In 2015 he and his co-founders - Todd Gottula and Todd Lee, both with serious enterprise software pedigrees - made a wager that looks obvious in retrospect and was anything but at the time. The wager was this: the next decade of healthcare value would be unlocked not by a new drug or a clever app, but by an honest, complete, queryable map of where every American patient goes, what happens to them, and what it costs. Build the map. The applications - networks, performance, real-world evidence, pricing intelligence - would follow.

Atlas, or: Google Maps for the U.S. patient population

The Atlas Platform is the spine. Think of it as a single, continuously updated graph that connects claims, clinical records, social determinants, prescription data, and provider performance metrics into one queryable layer. On top of Atlas sit the applications people actually buy: Clarify Care for provider benchmarking, Clarify Networks for payer network design, Clarify Markets for pricing and market intelligence, and Clarify Trials for real-world evidence in life sciences.

None of this sounds glamorous because none of it is. Glamour is for consumer products. Atlas is plumbing. But it is the plumbing that lets a payer ask, in seconds rather than quarters, which orthopedic surgeons in metro Houston deliver the best hip replacement outcomes adjusted for case mix, and what those outcomes actually cost. It lets a pharma company find the real-world cohort that matches their trial population. It lets a hospital CFO see which of their referral patterns are leaking revenue and which are saving lives.

Numbers people in expensive suits actually believe

Healthcare technology has a polite history of impressive demos and disappointing pilots. Clarify's proof is in who pays and who keeps paying. The customer roster includes national payers, academic medical centers, and an unusual number of provider organizations that have agreed to performance-tied pricing. The company has publicly said its economics are tied 100% to measurable results in some engagements - an arrangement consultants tend to politely refuse and software companies tend to politely avoid.

To pay for what works

If you ask Clarify employees what the company is for, you will get versions of the same answer. The American system pays for activity. It should pay for outcomes. The shift is hard because the measurement is hard. The measurement is hard because the data is fragmented. So Clarify unfragments the data. Everything else - the AI, the dashboards, the predictions - is downstream of that one stubborn commitment.

Healthcare IT has its share of mission statements built for the lobby wall. Clarify's is more honest than most. "Unlock the promise of value-based care with end-to-end intelligence on every patient journey." That is the sentence on the website. It does not get retired during a planning offsite because the company is, in fact, doing it.

The boring future that arrives anyway

There is a temptation in healthcare technology to lead with the moonshots. The AI radiologist. The longevity protocol. The personalized vaccine. Clarify's future does not look like that. Clarify's future looks like an analyst at a regional health plan answering a board question in nine minutes that used to take nine weeks. It looks like a pharma launch team finding the real-world cohort that will respond to a new therapy without spending a year and seven figures on a chart review. It looks like a provider network that finally knows which of its surgeons are quietly excellent and which are quietly expensive.

This is the boring part of the future. It is also the part that determines whether the next decade of American healthcare reform delivers or disappoints. Clarify is betting that the boring part is the most important part. So far, the customer list, the funding history, and the durability of the company's strategic story all suggest the bet is paying.

Back at 75 Hawthorne

That wall-sized monitor on the fourth floor is still there. The 300 million colored dots are still there. But the dots are doing something now. They are clustering into cohorts a clinical trial team needed yesterday. They are highlighting a referral pattern an academic medical center wanted to fix. They are pricing a value-based contract a payer is negotiating this afternoon.

The strangers are still strangers. They will never know Clarify Health exists. That is the deal. The company succeeds when its work is invisible and someone's hip replacement costs less, recovers faster, and gets measured honestly. Clarify Health is not the future of healthcare. It is the part of the future that lets the rest of the future happen.